OmniActive's Capsimax Shows 13% GLP-1 Increase, Raising Weight Management Ingredient Profile
A recent clinical study indicates OmniActive's Capsimax increased GLP-1 levels by 13% and improved exercise performance, positioning it as a key non-stimulant ingredient for weight management and sports nutrition formulations.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 24 April 2026
OmniActive Health Technologies has released findings from a new clinical study asserting that its Capsimax capsicum extract significantly elevated Glucagon-like Peptide-1 (GLP-1) levels by 13% after seven days of supplementation. The trial, conducted on resistance-trained men, also documented improved exercise performance. This research positions Capsimax as a compelling non-stimulant option for supplement formulations targeting weight management, satiety, and sports nutrition, offering metabolic enhancement, increased muscle endurance, and higher resting energy expenditure.
The study specifically supports the utility of plant-derived compounds in mitigating oxidative stress and accelerating post-exercise recovery, a critical consideration for athletes. Crucially, Capsimax maintains its thermogenic and metabolic advantages without the common adverse effects associated with direct capsaicin consumption, such as gastric irritation. This consumer-friendly profile broadens its market appeal, particularly for those seeking the benefits of capsaicin without discomfort.
The rising consumer awareness of GLP-1's role in satiety and weight management, driven by GLP-1 agonist medications, creates a substantial market opportunity for ingredients that can naturally support these pathways. Capsimax's demonstrated ability to increase endogenous GLP-1 levels allows brand owners to tap into this trend with a safe, well-tolerated, and scientifically backed ingredient.
What this means for United Kingdom
UK brand owners should immediately assess reformulation windows to integrate Capsimax into new or existing weight management and sports nutrition lines. With a 13% GLP-1 increase claim, products can target the growing demand for natural satiety and metabolic support, directly competing with synthetic options. Regulatory teams must ensure all marketing claims align with Advertising Standards Authority (ASA) guidelines regarding ingredient-specific health benefits, leveraging OmniActive's proprietary clinical data. Procurement leads should anticipate potential price adjustments or extended lead times given increased demand due to this new data, negotiating MOQs proactively. This development offers a clear competitive edge for brands that can swift to market with compliant, high-efficacy formulations.
For sports nutrition manufacturers, a non-stimulant ingredient enhancing endurance and recovery without gastric distress is invaluable. Market analysis indicates a strong consumer preference for natural ergogenic aids, and Capsimax fits this demand perfectly. This ingredient could command premium pricing in a sector increasingly focused on scientific efficacy and clean label credentials.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.